September 14, 2020 Lab Top-10 Microscopy

Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 15, 2020

Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 15, 2020 WALTHAM, Mass., Sept. 14, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the Morgan Stanley Global Healthcare Conference on... Read more

September 14, 2020 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Announces Collaborations to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization

Thermo Fisher Scientific Announces Collaborations to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science,... Read more

September 14, 2020 Uncategorized

Applying Connectomics to Retinal Disease

Research highlights use of ZEISS MultiSEM and ZEISS Sigma electron microscopes Globally, macular degeneration of the retina is a leading cause of legal blindness; however, little is known about its cause. A recent article by Dr. Charles Zucker, Staff Scientist at Harvard University, and colleagues describes electron microscopic observations from the retina of a woman... Read more

September 11, 2020 Chromatography Environ, Ag./Food & Bev Lab Top-10 Liq. Handling & Robotics M&A, Partnerships

Bruker Announces Acquisition of Canopy Biosciences, LLC

Strengthens Bruker in Targeted Multi-Omics and High-Plex Biomarker Imaging Adds Innovative ChipCytometry Tools for Multi-Dimensional Immune Profiling BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Canopy Biosciences, LLC, a leader in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy. This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based... Read more

September 11, 2020 Licensing, IP, and Legal Product Launch

New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data OCREVUS is the first and only treatment approved... Read more

September 10, 2020 Licensing, IP, and Legal

Xylem to participate in RBC Capital Markets Global Industrials Virtual Conference

RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 10, 2020– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and CEO, Patrick Decker, and Vice President of Investor Relations, Matt Latino, will participate in a virtual fireside chat hosted by RBC analyst Deane Dray... Read more

September 10, 2020 Product Launch

New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)

ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies. Pooled data from SAkura open-label extension (OLE) studies support continued effect of ENSPRYNG reducing risk of relapse in the longer term Ongoing data continues to show a favourable safety profile for ENSPRYNG ENSPRYNG was recently approved by the U.S. Food and Drug Administration... Read more

September 9, 2020 Life Science Tools Product Launch

PCR Biosystems launches RiboShield™ RNase Inhibitor to ensure reliable RNA protection

Caption: RiboShield™ RNase Inhibitor. Click images to download.  London, UK (09 September 2020) — PCR Biosystems has today launched RiboShield™ RNase Inhibitor. Already an important component of several PCR Biosystems kits, this robust and reliable RNase inhibitor is, for the first time, available as a standalone product. RiboShield™ RNase Inhibitor is a recombinant protein that blocks the activity of a... Read more

September 9, 2020 Lab Top-10 M&A, Partnerships Product Launch

Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis

Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis Combines bioproduction and pharma services to accelerate innovation in biologics manufacturing WALTHAM, Mass., Sept. 9, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri. The facility... Read more

September 9, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Phase IIIb clinical trial programme of higher-dose OCREVUS (ocrelizumab) to evaluate impact on reducing disability progression in RMS and PPMS OCREVUS CHIMES... Read more